Metastatic Colorectal Cancer Pipeline Drugs and Companies Insight Report (2022): Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments

Metastatic Colorectal Cancer Overview

Metastatic Colorectal Cancer is a cancer that begins in the colon or rectum an metastasized. This means it has spread to regional or distant sites, such as other organs or lymph nodes. The most common places for colorectal cancer to spread are the liver, lung, and peritoneum. But cancer can also spread to other parts of your body, such as the bones and brain. Colorectal cancer (CRC) is the third most common cause of cancer mortality worldwide with more than 1.85 million cases and850 000 deaths annually. Of new colorectal cancer diagnoses, 20% of patients have metastatic disease at presentation and another 25% who present with localized disease will later develop metastases.

“Metastatic Colorectal Cancer Pipeline Insight, 2022″ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Metastatic Colorectal Cancer Market. 

The Metastatic Colorectal Cancer Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details. 

Some of the key takeaways from the Metastatic Colorectal Cancer Pipeline Report:

• Companies across the globe are diligently working toward developing novel Metastatic Colorectal Cancer treatment therapies with a considerable amount of success over the years. Metastatic Colorectal Cancer Key players such as – Celyad Oncology, Roche, Nektar Therapeutics, Treos Bio, Sunshine Guojian Pharmaceutical, Symphogen A/S, Scandion Oncology A/S, G1 Therapeutics, Mirati Therapeutics, and others, are developing therapies for the Metastatic Colorectal Cancer treatment 

• Metastatic Colorectal Cancer Emerging therapies such as – CYAD 101, RG6286, NKTR-255, PolyPEPI 1018, CPGJ602, Sym004, SCO-101, Trilaciclib, MRTX849, and others are expected to have a significant impact on the Metastatic Colorectal Cancer market in the coming years.   
• In August 2020, G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, and Simcere Pharmaceutical Group, a pharmaceutical company rapidly transitioning to an innovative and R&D-driven company in China, announced an exclusive license agreement for the development and commercialization of trilaciclibacross all indications in Greater China (mainland China, Hong Kong, Macau and Taiwan). 

Metastatic Colorectal Cancer Pipeline Therapeutics Assessment

• Metastatic Colorectal Cancer Assessment by Product Type
• Metastatic Colorectal Cancer By Stage and Product Type
• Metastatic Colorectal Cancer Assessment by Route of Administration
• Metastatic Colorectal Cancer By Stage and Route of Administration
• Metastatic Colorectal Cancer Assessment by Molecule Type
• Metastatic Colorectal Cancer by Stage and Molecule Type 

DelveInsight’s Metastatic Colorectal Cancer Report covers around 140+ products under different phases of clinical development like

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration 

Emerging Metastatic Colorectal Cancer Drugs Under Different Phases of Clinical Development Include:

• CYAD 101: Celyad Oncology
• RG6286: Roche
• NKTR-255: Nektar Therapeutics
• PolyPEPI 1018: Treos Bio
• CPGJ602: Sunshine Guojian Pharmaceutical
• Sym004: Symphogen A/S
• SCO-101: Scandion Oncology A/S
• Trilaciclib: G1 Therapeutics
• MRTX849: Mirati Therapeutics 

Request for Sample PDF Report for Metastatic Colorectal Cancer Pipeline Assessment and clinical trials

Metastatic Colorectal Cancer Pipeline Analysis:

The Metastatic Colorectal Cancer pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the Metastatic Colorectal Cancer treatment with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Metastatic Colorectal Cancer Treatment.
• Metastatic Colorectal Cancer key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Metastatic Colorectal Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Metastatic Colorectal Cancer market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Further Metastatic Colorectal Cancer product details are provided in the report. Download the Metastatic Colorectal Cancer pipeline report to learn more about the emerging Metastatic Colorectal Cancer therapies

Metastatic Colorectal Cancer Pipeline Market Drivers

• Rising incidence of Metastatic Colorectal Cancer
• Increase in collaborations among industries to develop novel therapies for metastatic colorectal cancer

Metastatic Colorectal Cancer Pipeline Market Barriers

• High-cost involved with Metastatic Colorectal Cancer treatments
• There is no universal regimen that can easily treat every patient with equal efficacy

Get a Free Sample PDF Report to know more about Metastatic Colorectal Cancer Pipeline Assessment-

Scope of Metastatic Colorectal Cancer Pipeline Drug Insight    

• Coverage: Global
• Key Metastatic Colorectal Cancer Companies: Celyad Oncology, Roche, Nektar Therapeutics, Treos Bio, Sunshine Guojian Pharmaceutical, Symphogen A/S, Scandion Oncology A/S, G1 Therapeutics, Mirati Therapeutics, and others
• Key Metastatic Colorectal Cancer Therapies: CYAD 101, RG6286, NKTR-255, PolyPEPI 1018, CPGJ602, Sym004, SCO-101, Trilaciclib, MRTX849, and others
• Metastatic Colorectal Cancer Therapeutic Assessment: Metastatic Colorectal Cancer current marketed and Metastatic Colorectal Cancer emerging therapies
• Metastatic Colorectal Cancer Market Dynamics:  Metastatic Colorectal Cancer market drivers and Metastatic Colorectal Cancer market barriers

Table of Contents

Download Sample PDF Report to know more about Metastatic Colorectal Cancer drugs and therapies

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: +91 9568243403
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com